Digital therapeutics is the wave of the future in healthcare. The psychedelic drug industry is at the forefront for this new tech.
Digital therapeutics is the wave of the future in healthcare. The psychedelic drug industry is at the forefront for this new tech.
A recent study shows HALF of all adults already experiencing anxiety due to the social isolation from COVID-19 lockdowns. COVID Isolation Syndrome.
Forty years ago, cannabis was labelled "a Gateway Drug" to harder drug use -- such as psychedelics. Today, cannabis is the Gateway Drug to psychedelics legalization.
Two pandemics are currently afflicting the planet. While our governments focus on the smaller one (COVID-19), the larger one (the Mental Health Crisis) is rapidly spiralling out of control.
Both the atai Life Sciences IPO and a MindMed uplisting to the NASDAQ are highly anticipated events. They could occur within weeks -- or even days -- of each other.
Drug development is expensive. It is also EXTREMELY lucrative. We take a close look at this revenue potential.
Psychedelic stocks have been hammered in recent weeks by general selling pressures on tech stocks. But with corporate coffers full, these companies can weather the storm.
Psychedelic stocks have been battered by general market headwinds in recent weeks. Uncertainty could persist. How do investors allocate capital?
The COVID pandemic is making the need for psychedelic drugs and the commercial potential of the industry much greater. But there is a catch.
One huge market. Six horses in the race (so far). Lots of prize money to go around.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now